Page 110 - Read Online

Page 288 Cencioni. Neuroimmunol Neuroinflammation 2020;7:277-90 I http://dx.doi.org/10.20517/2347-8659.2020.18

PD-1 immune checkpoint blockade. Nat Cancer 2020:1:75–85.
22. Strauss L, Mahmoud MAA, Weaver JD, Tijaro-Ovalle NM, Christofides A, et al. Targeted deletion of PD-1 in myeloid cells induces
antitumor immunity. Sci Immunol 2020;5:eaay1863.
23. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine 2012;42:252-65.
24. Armengol MP, Juan M, Lucas-Martín A, Fernández-Figueras MT, Jaraquemada D, et al. Thyroid autoimmune disease: demonstration of
thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal
centers. Am J Pathol 2001;159:861-73.
25. Ruiz-Riol M, Barnils Mdel P, Colobran Oriol R, Pla AS, Borràs Serres FE, et al. Analysis of the cumulative changes in Graves’ disease
thyroid glands points to IFN signature, plasmacytoid DCs and alternatively activated macrophages as chronicity determining factors. J
Autoimmun 2011;36:189-200.
26. Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, et al. Endocrine toxicity of cancer immunotherapy targeting immune
checkpoints. Endocr Rev 2019;40:17-65.
27. Álvarez-Sierra D, Marín-Sánchez A, Ruiz-Blázquez P, de Jesús Gil C, Iglesias-Felip C, et al. Analysis of the PD-1/PD-L1 axis in human
autoimmune thyroid disease: insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun
2019;103:102285.
28. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, et al. Identification of cell types responsible for bone resorption in
rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-51.
29. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation
factor. Arthritis Rheum 2000;43:250-8.
30. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, et al. Expression of osteoclast differentiation factor in rheumatoid arthritis.
Arthritis Rheum 2000;43:2523-30.
31. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
32. van der Woude D, Houwing-Duistermaat JJ, Toes RE, Huizinga TW, Thomson W, et al. Quantitative heritability of anti-citrullinated
protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009;60:916-23.
33. Carlens C, Hergens MP, Grunewald J, Ekbom A, Eklund A, et al. Smoking, use of moist snuff, and risk of chronic inflammatory diseases.
Am J Respir Crit Care Med 2010;181:1217-22.
34. Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, et al. Pathologically expanded peripheral T helper cell subset drives B
cells in rheumatoid arthritis. Nature 2017;542:110-4.
35. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
36. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-
interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Arthritis Rheum 2002;46:3143-50.
37. VanderBorght A, Geusens P, Raus J, Stinissen P. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and
new immunotherapies. Semin Arthritis Rheum 2001;31:160-75.
38. Kong EK, Prokunina-Olsson L, Wong WH, Lau CS, Chan TM, et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis
in Hong Kong Chinese. Arthritis Rheum 2005;52:1058-62.
39. Prokunina L, Padyukov L, Bennet A, de Faire U, Wiman B, et al. Association of the PD-1.3A allele of the PDCD1 gene in patients with
rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 2004;50:1770-3.
40. Wan B, Nie H, Liu A, Feng G, He D, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in
rheumatoid arthritis. J Immunol. 2006;177:8844-50.
41. Li S, Liao W, Chen M, Shan S, Song Y, et al. Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid
arthritis. Inflammation 2014;37:116-21.
42. Shivaleela C, Suresh BS, Kumar GV, Lakshmiprabha S. Morphological study of the supracondylar process of the humerus and its clinical
implications. J Clin Diagn Res 2014;8:1-3.
43. Xu J, He Y, Wang J, Li X, Huang L, et al. Influence of the TNFSF4 rs1234315 polymorphism in the susceptibility to systemic lupus
erythematosus and rheumatoid arthritis. Hum Immunol 2019;80:270-5.
44. Gambino CM, Aiello A, Accardi G, Caruso C, Candore G. Autoimmune diseases and 8.1 ancestral haplotype: An update. HLA
2018;92:137-43.
45. Gao J, Gai N, Wang L, Liu K, Liu XH, et al. Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus
erythematosus risk. Oncotarget 2017;8:36885-97.
46. Al-Motwee S, Jawdat D, Jehani GS, Anazi H, Shubaili A, et al. Association of HLA-DRB1*15 and HLADQB1*06 with SLE in Saudis.
Ann Saudi Med 2013;33:229-34.
47. Gao Z, Li X, Peng T, Hu Z, Liu J, et al. Systemic lupus erythematosus with Guillian-Barre syndrome: a case report and literature review.
Medicine (Baltimore) 2018;97:e11160.
48. Mahmoudi M, Rezaiemanesh A, Salmaninejad A, Harsini S, Poursani S, et al. PDCD1 single nucleotide genes polymorphisms confer
susceptibility to juvenile-onset systemic lupus erythematosus. Autoimmunity 2015;48:488-93.
49. Ferreiros-Vidal I, Gomez-Reino JJ, Barros F, Carracedo A, Carreira P, et al. Association of PDCD1 with susceptibility to systemic lupus
erythematosus: evidence of population-specific effects. Arthritis Rheum 2004;50:2590-7.
50. Rocha MC, Santos LM, Bagatin E, Cohen Tervaert JW, Damoiseaux JG, et al. Genetic polymorphisms and surface expression of CTLA-4
and PD-1 on T cells of silica-exposed workers. Int J Hyg Environ Health 2012;215:562-9.